Biovica has been selected by the European Commission to receive support for a project as part of the Horizon 2020 phase 2 program. Biovica’s project “Clinical validation of the DiviTum assay in two high profile clinical studies in Europe” is receiving € 682,000 and being undertaken with a European cancer study group and Karolinska Institutet, according to Biovica.
DiviTum™ is a blood test developed by Biovica as a highly sensitive assay for measuring cell proliferation rate. DiviTum™ measures an enzyme with a key function in cell division and the rate in which tumor cells grow. DiviTum™ has demonstrated unique values in cancer, predicting therapy efficacy and monitoring the status of the disease and treatment, according to the company.
During the project, DiviTum™ will be assessed as a companion tool to evaluate efficacy of a new cancer drug that was recently approved. The goal of the project is to further establish that DiviTum™ acts as a predictive and monitoring biomarker in solid tumors, Biovica notes.
The European Commission received 614 proposals, but only 42 were selected for funding.
”We are very pleased that our study program in collaboration with our distinguished partners is supported in phase 2 of the Horizon 2020 program. I am especially pleased that we received an excellent evaluation score and that the Commission believes that our project will give a high impact,” says Anders Rylander, Biovica’s CEO.